Treatment of Thyroid Eye Disease

被引:0
|
作者
Margaret E. Phillips
Mehrak M. Marzban
Sajeev S. Kathuria
机构
[1] University of Maryland,Department of Ophthalmology
来源
关键词
West Nile Virus; Progressive Multifocal Leukoencephalopathy; Euthyroid State; Eyelid Retraction; Orbital Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
Thyroid eye disease (TED) is an autoimmune disease characterized by varying degrees of proptosis, congestion and inflammation of the extraocular tissues, and eyelid retraction. It is usually seen in the setting of Graves’ disease, but the severity of TED does not necessarily correlate with the level of systemic disease in a given patient. It is very important, nonetheless, to try to achieve a euthyroid state to minimize the chances of exacerbation of TED. Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking, because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations. Once there is significant improvement in the acute inflammation, it is useful to treat patients who have residual inflammation with external beam radiation in order to be able to wean the patient off steroids and avoid their well-known complications.
引用
收藏
页码:64 / 69
页数:5
相关论文
共 50 条
  • [21] Teprotumumab for the treatment of chronic thyroid eye disease
    Ugradar, Shoaib
    Kang, Julia
    Kossler, Andrea L.
    Zimmerman, Erin
    Braun, Jenna
    Harrison, Andrew R.
    Bose, Swaraj
    Cockerham, Kimberly
    Douglas, Raymond S.
    EYE, 2022, 36 (08) : 1553 - 1559
  • [22] Treatment of Hyperthyroidism in Graves' Disease Complicated by Thyroid Eye Disease
    Bartalena, Luigi
    Smith, Terry J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025, 110 (04): : 922 - 930
  • [23] Recent Developments in the Medical Treatment of Thyroid Eye Disease
    Krassas, G. E.
    Boboridis, K.
    ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY, 2006, 25 (02): : 117 - 122
  • [24] The relationship between thyroid eye disease and radioiodine treatment
    Thou, Sarameth
    Vinjamuri, Sobhan
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (03) : 194 - 198
  • [25] Severe Hyperglycemia with Teprotumumab for Treatment of Thyroid Eye Disease
    Cottom, Savannah
    Barrientez, Brayden
    Melson, Andrew
    CASE REPORTS IN OPHTHALMOLOGY, 2024, 15 (01): : 246 - 249
  • [26] Rituximab in the Treatment of Thyroid Eye Disease: Science Fiction?
    Salvi, Mario
    Vannucchi, Guia
    Campi, Irene
    Beck-Peccoz, Paolo
    ORBIT-AN INTERNATIONAL JOURNAL ON ORBITAL DISORDERS AND FACIAL RECONSTRUCTIVE SURGERY, 2009, 28 (04): : 251 - 255
  • [27] Thyroid Eye Disease: Navigating the New Treatment Landscape
    Dosiou, Chrysoula
    Kossler, Andrea Lora
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (05)
  • [28] Re: "Teprotumumab for the Treatment of Recalcitrant Thyroid Eye Disease"
    Perry, Julian D.
    Hwang, Catherine J.
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2025, 41 (01): : 112 - 112
  • [29] FDA approves first treatment for thyroid eye disease
    不详
    NURSE PRACTITIONER, 2020, 45 (06): : 56 - 56
  • [30] Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease
    Vargason, Caroline W.
    Chelnis, James G.
    Barahimi, Behin I.
    Mawn, Louise A.
    SEMINARS IN OPHTHALMOLOGY, 2016, 31 (04) : 409 - 414